Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2011

View Archived Issues

Pfizer claims novel agents for Gram-negative bacterial infections

Celecoxib may prevent lung cancer development/progression in former smokers

Metabolic Solutions Development begins phase II trial of MSDC-0160 in Alzheimer's disease

Final HORIZONS-AMI data favor bivalirudin and Taxus paclitaxel-eluting stent in STEMI

Evotec discloses new voltage-gated K(V)1.3 potassium channel blockers

Servier patents novel histamine H3 receptor antagonists

Novel GC-C agonists disclosed by Ironwood Pharmaceuticals

Everolimus improves response to trastuzumab in metastatic breast cancer

Celprogen's neuronal trans-differentiated stem cells show promise in models of Alzheimer's disease

Cardioxyl and Johns Hopkins University synthesize new nitroxyl donors

Aslan Pharmaceuticals licenses ARRY-543 from Array BioPharma

PU-H71 enters first-in-human phase I study in advanced malignancies

Lupus treatment Benlysta gains European marketing approval

Novel nNOS inhibitor displays potent analgesic effects in preclinical tests

Phase II trial shows aviscumine may improve survival in metastatic melanoma

OncoVista Innovative Therapies begins additional animal safety study of OVI-117

FDA's ODAC recommends accelerated approval of Adcetris for Hodgkin's lymphoma and ACLC

BioMarin's BMN-673 enters phase I trial in advanced hematological malignancies

Chugai seeks Japanese approval of Pulmozyme to improve pulmonary function in cystic fibrosis

Evolva completes phase I studies of EV-077

Vical and Astellas Pharma enter worldwide license agreements for TransVax cytomegalovirus vaccine

Pertuzumab/trastuzumab/docetaxel improves progression-free survival in HER2+ breast cancer

Development of Impax's IPX-066 for Parkinson's disease supported by Michael J. Fox Foundation grant

Biotec Pharmacon reports phase I/II data on SBG/3F8 combination in pediatric neuroblastoma

FDA issues complete response letter for resubmitted Intermezzo NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...